TITLE

Effects of the short-term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI

AUTHOR(S)
PENG WEI; YI-GANG ZHANG; LIN LING; ZI-QI TAO; LI-YA JI; JIE BAI; BIN ZONG; CHUN-YING JIANG; QIAN ZHANG; QIANG FU; XIANG-JUN YANG
PUB. DATE
November 2016
SOURCE
Experimental & Therapeutic Medicine;Nov2016, Vol. 12 Issue 5, p2861
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The aim of the present study was to determine the effects of the short-term application of pantoprazole on the co-treatment of acute ST-segment elevation myocardial infarction (STEMI) with aspirin and clopidogrel. A total of 207 acute patients showing primary symptoms of STEMI, who received successful emergent percutaneous coronary intervention treatment during hospitalization were randomly divided into two groups. In the test group proton pump inhibitors (PPIs), the patients were treated with a combination of aspirin and clopidogrel and pantoprazole, while those in the control group were treated only with aspirin and clopidogrel. Gastrointestinal bleeding events and major adverse cardiac events (MACEs) were observed in the two groups. Gastrointestinal bleeding events of the two groups mostly occurred within the first week of hospitalization, although the incidence in the PPIs group was significantly higher than that in the control group (p<0.05). However, no significant difference was observed for the incidence of MACEs between the two groups (p>0.05). In conclusion, the results of the present study have shown that the short-term application of pantoprazole combined with aspirin and clopidogrel does not increase the incidence of MACEs in patients with acute STEMI, reduces the risk of gastrointestinal bleeding, and is thus worth promoting clinically, particularly for high-risk groups.
ACCESSION #
119181887

 

Related Articles

  • Proton Pump Inhibitors and Clopidogrel. Karpman, Harold L. // Internal Medicine Alert;6/29/2011, Vol. 33 Issue 12, p92 

    Proton pump inhibitor use in clopidogreltreated post-percutaneous coronary intervention patients was not associated with an increased risk of all-cause death, nonfatal myocardial infarction, repeat revascularization, or major adverse cardiovascular events.

  • Combining PPI and aspirin increases CVD event risk.  // Pulse;6/8/2011, Vol. 71 Issue 21, p9 

    The article reports on the result of the study which suggests that prescribing proton-pump inhibitors to myocardial infarction patients on aspirin can increase their risk of cardiovascular events.

  • Clopidogrel plus proton pump inhibitor linked with increased risk for rehospitalization.  // Cardiology Today;Jun2010, Vol. 13 Issue 6, p32 

    The article presents a study about the link between combined clopidogrel and proton pump inhibitor and rehospitalization after a myocardial infarction (MI) or stent placement, published in an issue of "Archives of Internal Medicine."

  • Prescribing proton pump inhibitors with clopidogrel. Targownik, Laura Ellyn // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/11/2012, Vol. 345 Issue 7869, p6 

    The author comments on a study by Douglas and colleagues who analysed whether proton pump inhibitors (PPIs) cause myocardial infarction in users of aspirin and clopidogrel. The study concluded that once residual confounding is minimised no association exists between myocardial infarction and PPI...

  • Clopidogrel plus proton pump inhibitor linked with increased risk for rehospitalization.  // Hem/Onc Today;5/25/2010, Vol. 11 Issue 10, p8 

    The article discusses the study about the impact of taking clopidrogel combined with proton pump inhibitor on risk for rehospitalization following a myocardial infarction or stent placement by researchers from Irvine, California and Seattle.

  • Review Article: Combination of Clopidogrel and Proton Pump Inhibitors: Implications for Clinicians. Tran, Marie; Tafreshi, Javad; Pai, Ramdas G. // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2010, Vol. 15 Issue 4, p326 

    Objectives: To evaluate the existing literature on a proposed interaction between clopidogrel and proton pump inhibitors (PPIs) and discuss its implications for clinicians treating patients with this combination therapy. Background: Each year millions of patients receive antiplatelet therapy. A...

  • Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin. Waksman, Ron; Gaglia Jr., Michael A. // Evidence Based Medicine;Jun2013, Vol. 18 Issue 3, Following pe30 

    The authors comment on a study by Ron Waksman and colleagues to evaluate the association between clopidogrel and interaction with proton pump inhibitors (PPIs). The study found that no relationship existed between PPIs and adverse events in patients taking clopidogrel and aspirin. They commented...

  • The aspirin question.  // Consumer Reports on Health;Jun2013, Vol. 25 Issue 6, p6 

    The article reports on the prevalence of heart attacks and strokes among U.S. consumers and discusses the role that a low dose aspirin regimen can play in preventing heart attacks and strokes. A discussion of medical complications which can be associated with aspirin, and of aspirin alternatives...

  • COGENT proof of clopidogrel/PPI's tolerability.  // Reactions Weekly;10/31/2009, Issue 1276, p3 

    The article discusses research on omeprazole in patients receiving aspirin and clopidogrel. It references a study by D. L. Bhatt, presented at the 21st Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics. The trial shows that the combination of a gastro-protecting proton...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics